Thalidomide-based multidisciplinary treatment for patients with advanced hepatocellular carcinoma: A retrospective analysis

Table 4 Comparison of patients who responded and patients with progressive disease

Characteristic	CR	PR	SD	PD	CR + PR + SD	P valuea
AFP level						0.357
> 400 ng/mL	0 (0)	1 (3.2)	6 (19.4)	24 (77.4)	7 (22.6)
< 400 ng/mL	1 (4.6)	4 (18.2)	3 (13.6)	14 (63.6)	8 (36.4)
A decrease in AFP > 50% after treatment	1 (6.3)	4 (25.0)	2 (12.5)	9 (56.3)	7 (43.8)	0.182
Overall survival, mo	66.8	NA	20.7 (95% CI: 20.7-33.3)	6.9 (95% CI: 6.3-10.8)	33.3 (95% CI: 20.7-NA)	0.003b

AFP: Alpha fetoprotein; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; NA: Not assessable.

^aP < 0.05 between the two groups (CR + PR + SD vs PD);

^bP = 0.0003 (less than 0.005) between progress disease and CR + PR + SD.